Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Arboviral Encephalitis01:25

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression.

Molecular psychiatry·2026
Same author

Language and communication disorders in dementia with Lewy bodies versus Alzheimer's disease: Objective screening and subjective perspectives of patients, their caregivers and clinicians.

Journal of Alzheimer's disease : JAD·2026
Same author

Probing biomass mimic guaiacol confinement and interactions in ZSM-5 zeolite.

Materials chemistry frontiers·2026
Same author

Regional gene expression and brain atrophy in dementia with Lewy bodies: an imaging transcriptomics study.

NPJ Parkinson's disease·2026
Same author

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

CNS drugs·2026
Same author

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.

Neurology·2026

Related Experiment Video

Updated: May 7, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.

Olivier Outteryck1, Hélène Zéphir2, Julia Salleron3

  • 1Department of Neurology, Université Lille Nord de France (EA2686), France olivier.outteryck@chru-lille.fr.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|September 28, 2013
PubMed
Summary

JC virus (JCV) reactivation is common in multiple sclerosis (MS) patients on natalizumab (NTZ) therapy, leading to increased anti-JCV antibody levels detectable by newer tests.

Keywords:
JC virusMultiple sclerosisnatalizumabprogressive multiple leukoencephalopathyquantitative results

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Related Experiment Videos

Last Updated: May 7, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Area of Science:

  • Neuroimmunology
  • Virology
  • Clinical Immunology

Background:

  • Natalizumab (NTZ) is an effective treatment for multiple sclerosis (MS).
  • JC virus (JCV) poses a risk for MS patients on NTZ due to potential for progressive multifocal leukoencephalopathy (PML).
  • Monitoring JCV serostatus is crucial for risk stratification in MS patients receiving NTZ.

Purpose of the Study:

  • To evaluate JCV seroconversion and seroreversion rates in French MS patients on NTZ.
  • To characterize the MS population undergoing JCV serological testing.
  • To identify risk factors for JCV seropositivity and assess the utility of quantitative JCV serology.

Main Methods:

  • Analysis of JCV serological status in 357 MS patients from two French centers, with initial testing in 2011 using a first-generation ELISA (Gen1).
  • Evaluation of JCV seroconversion over one year using a second-generation ELISA (Gen2) in 303 patients.
  • Multivariate analysis to determine risk factors for JCV seropositivity and analyze quantitative serology results.

Main Results:

  • Among 165 patients initially JCV-seronegative, the seroconversion rate to JCV-positive was 26.67% within one year using Gen2 testing.
  • A higher-than-expected proportion (14.5%) of patients became anti-JCV antibody seroconverters.
  • Increasing anti-JCV antibody index values were observed over time in seroconverting patients.

Conclusions:

  • JC virus reactivation appears to occur during natalizumab therapy in MS patients.
  • Reactivation leads to elevated anti-JCV antibody titers, enhancing detection by second-generation ELISA tests.
  • These findings underscore the importance of monitoring JCV status in MS patients treated with NTZ.